Diabetes, Cardiovascular & Renal Complications
28 Nov 2012 - 29 Nov 2012 - London, UK
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Plus an interactive pre–conference workshop
Tuesday 27th November 2012, The Copthorne Tara Hotel, London
Cardio-renal risk in type 2 diabetes information from clinical trials:
What we have, what do we need to know?
Workshop leader: Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, King’s College London
To register visit http://www.smi-online.co.uk/goto/diabetes-conference7.asp alternatively contact Fateja Begum on email@example.com